These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6465106)

  • 1. A unique postmarket outpatient surveillance program of cimetidine: report on phase II and final summary.
    Humphries TJ; Myerson RM; Gifford LM; Aeugle ME; Josie ME; Wood SL; Tannenbaum PJ
    Am J Gastroenterol; 1984 Aug; 79(8):593-6. PubMed ID: 6465106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cimetidine postmarket outpatient surveillance program. Interim report on phase I.
    Gifford LM; Aeugle ME; Myerson RM; Tannenbaum PJ
    JAMA; 1980 Apr; 243(15):1532-5. PubMed ID: 7359735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report.
    Colin Jones DG; Langman MJ; Lawson DH; Vessey MP
    Q J Med; 1985 Mar; 54(215):253-68. PubMed ID: 3991880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug surveillance. Monitoring the side-effects of drugs in the post-marketing phase: cimetidine. II].
    Mariani L; Minora T
    Clin Ter; 1984 Apr; 109(2):109-25. PubMed ID: 6234121
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety profile of orlistat: results of a prescription-event monitoring study.
    Acharya NV; Wilton LV; Shakir SA
    Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients.
    Griessinger N; Sittl R; Likar R
    Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
    Lode H; Vogel F; Elies W
    Clin Ther; 1999 Jan; 21(1):61-74; discussion 1-2. PubMed ID: 10090425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of age on reporting of adverse clinical events: results from two postmarketing surveillance methods.
    Bryant SG; Fisher S; Prinsley DM; Olins NJ; Larson DB
    Pharmacotherapy; 1991; 11(3):249-55. PubMed ID: 1862016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmarket surveillance. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Jun; 67(109):38878-92. PubMed ID: 12053947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system.
    Ortega A; Aguinagalde A; Lacasa C; Aquerreta I; Fernández-Benítez M; Fernández LM
    Ann Pharmacother; 2008 Oct; 42(10):1491-6. PubMed ID: 18780808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergency department visits for outpatient adverse drug events: demonstration for a national surveillance system.
    Budnitz DS; Pollock DA; Mendelsohn AB; Weidenbach KN; McDonald AK; Annest JL
    Ann Emerg Med; 2005 Feb; 45(2):197-206. PubMed ID: 15671977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical tolerability profile of alendronate.
    Watts N; Freedholm D; Daifotis A
    Int J Clin Pract Suppl; 1999 Apr; 101():51-61. PubMed ID: 12669741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events in a multicenter phase IV study of propofol: evaluation by anesthesiologists and postanesthesia care unit nurses.
    McLeskey CH; Walawander CA; Nahrwold ML; Roizen MF; Stanley TH; Thisted RA; White PF; Apfelbaum JL; Grasela TH; Hug CC
    Anesth Analg; 1993 Oct; 77(4 Suppl):S3-9. PubMed ID: 8214694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective evaluation of cimetidine drug use.
    Kowalsky SF; Andritz MB; Hamilton RA; Platek TE
    Hosp Pharm; 1989 Feb; 24(2):105-8. PubMed ID: 10292189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient reporting of adverse drug reactions: useful information for pain management?
    Jarernsiripornkul N; Krska J; Richards RM; Capps PA
    Eur J Pain; 2003; 7(3):219-24. PubMed ID: 12725844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A postmarketing surveillance evaluation of quinapril in 3742 Canadian hypertensive patients: the ACCEPT Study. Accupril Canadian Clinical Evaluation and Patient Teaching.
    Larochelle P; Haynes B; Maron N; Dugas S
    Clin Ther; 1994; 16(5):838-53. PubMed ID: 7859244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA; Brushwood DB
    J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics.
    Bender S; Grohmann R; Engel RR; Degner D; Dittmann-Balcar A; Rüther E
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S46-53. PubMed ID: 15052514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A post-marketing surveillance study of Voltarol 75 mg SR in the primary care setting.
    Jones CW
    Br J Clin Pract; 1996; 50(7):390-5. PubMed ID: 9015913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.